[go: up one dir, main page]

WO2024011150A3 - Cns targeting complexes and uses thereof - Google Patents

Cns targeting complexes and uses thereof Download PDF

Info

Publication number
WO2024011150A3
WO2024011150A3 PCT/US2023/069671 US2023069671W WO2024011150A3 WO 2024011150 A3 WO2024011150 A3 WO 2024011150A3 US 2023069671 W US2023069671 W US 2023069671W WO 2024011150 A3 WO2024011150 A3 WO 2024011150A3
Authority
WO
WIPO (PCT)
Prior art keywords
cns
cells
targeting complexes
complexes
cns targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/069671
Other languages
French (fr)
Other versions
WO2024011150A2 (en
Inventor
Jonathan MCNEILL
Stefano ZANOTTI
Kim TANG
Jin CUI
Susana CORREIA
Oxana Beskrovnaya
Romesh R. SUBRAMANIAN
Mohammed T. QATANANI
Timothy Weeden
Cody A. DESJARDINS
Brendan QUINN
John NAJIM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dyne Therapeutics Inc
Original Assignee
Dyne Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN202380062801.8A priority Critical patent/CN119790075A/en
Application filed by Dyne Therapeutics Inc filed Critical Dyne Therapeutics Inc
Priority to AU2023303022A priority patent/AU2023303022A1/en
Priority to IL317868A priority patent/IL317868A/en
Priority to MA71403A priority patent/MA71403A/en
Priority to CA3260578A priority patent/CA3260578A1/en
Priority to EP23836258.6A priority patent/EP4551251A2/en
Priority to KR1020257003324A priority patent/KR20250035552A/en
Priority to JP2025500080A priority patent/JP2025522877A/en
Publication of WO2024011150A2 publication Critical patent/WO2024011150A2/en
Publication of WO2024011150A3 publication Critical patent/WO2024011150A3/en
Priority to MX2024015868A priority patent/MX2024015868A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present application relates to complexes comprising a central nervous system (CNS)-targeting agent covalently linked to a molecular payload (e.g., an oligonucleotide, polypeptide, small molecule, or gene therapy pay load) for delivery to cells (e.g., cells of the CNS) and uses thereof, particularly uses relating to treatment of disease.
PCT/US2023/069671 2022-07-06 2023-07-06 Cns targeting complexes and uses thereof Ceased WO2024011150A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2025500080A JP2025522877A (en) 2022-07-06 2023-07-06 CNS targeting complexes and uses thereof
AU2023303022A AU2023303022A1 (en) 2022-07-06 2023-07-06 Cns targeting complexes and uses thereof
IL317868A IL317868A (en) 2022-07-06 2023-07-06 Cns targeting complexes and uses thereof
MA71403A MA71403A (en) 2022-07-06 2023-07-06 CNS TARGETING COMPLEXES AND THEIR USES
CA3260578A CA3260578A1 (en) 2022-07-06 2023-07-06 Cns targeting complexes and uses thereof
CN202380062801.8A CN119790075A (en) 2022-07-06 2023-07-06 CNS targeting complexes and uses thereof
KR1020257003324A KR20250035552A (en) 2022-07-06 2023-07-06 CNS targeting complex and uses thereof
EP23836258.6A EP4551251A2 (en) 2022-07-06 2023-07-06 Cns targeting complexes and uses thereof
MX2024015868A MX2024015868A (en) 2022-07-06 2024-12-17 Cns targeting complexes and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263367814P 2022-07-06 2022-07-06
US63/367,814 2022-07-06
US202363496184P 2023-04-14 2023-04-14
US63/496,184 2023-04-14

Publications (2)

Publication Number Publication Date
WO2024011150A2 WO2024011150A2 (en) 2024-01-11
WO2024011150A3 true WO2024011150A3 (en) 2024-03-07

Family

ID=89454151

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/069671 Ceased WO2024011150A2 (en) 2022-07-06 2023-07-06 Cns targeting complexes and uses thereof

Country Status (10)

Country Link
EP (1) EP4551251A2 (en)
JP (1) JP2025522877A (en)
KR (1) KR20250035552A (en)
CN (1) CN119790075A (en)
AU (1) AU2023303022A1 (en)
CA (1) CA3260578A1 (en)
IL (1) IL317868A (en)
MA (1) MA71403A (en)
MX (1) MX2024015868A (en)
WO (1) WO2024011150A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021533200A (en) 2018-08-02 2021-12-02 ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. Muscle-targeted complexes and their use for treating facial, scapular, and brachial muscular dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US20210308273A1 (en) 2018-08-02 2021-10-07 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
EP4366784A1 (en) 2021-07-09 2024-05-15 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
KR20250004770A (en) 2022-04-15 2025-01-08 다인 세라퓨틱스, 인크. Muscle-targeting complexes and preparations for treating myotonic dystrophy
WO2025193741A1 (en) * 2024-03-12 2025-09-18 Vrata Therapeutics, Inc. 3e10 antibody nucleic acid conjugates

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150238637A1 (en) * 2005-09-27 2015-08-27 National Research Council Of Canada Blood-brain Barrier Epitopes and Uses Thereof
WO2022020106A1 (en) * 2020-07-23 2022-01-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150238637A1 (en) * 2005-09-27 2015-08-27 National Research Council Of Canada Blood-brain Barrier Epitopes and Uses Thereof
WO2022020106A1 (en) * 2020-07-23 2022-01-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy

Also Published As

Publication number Publication date
CA3260578A1 (en) 2024-01-11
WO2024011150A2 (en) 2024-01-11
IL317868A (en) 2025-02-01
JP2025522877A (en) 2025-07-17
AU2023303022A1 (en) 2025-01-02
MA71403A (en) 2025-04-30
MX2024015868A (en) 2025-04-02
KR20250035552A (en) 2025-03-12
CN119790075A (en) 2025-04-08
EP4551251A2 (en) 2025-05-14

Similar Documents

Publication Publication Date Title
WO2024011150A3 (en) Cns targeting complexes and uses thereof
Benoit et al. Nanoparticles for oral biofilm treatments
Liu et al. Engineered interactions with mesoporous silica facilitate intracellular delivery of proteins and gene editing
Jiang et al. Chitosan-graft-polyethylenimine as a gene carrier
Ghosh et al. Intracellular delivery of a membrane-impermeable enzyme in active form using functionalized gold nanoparticles
Veerapandian et al. Functionalization of biomolecules on nanoparticles: specialized for antibacterial applications
US6696038B1 (en) Cationic lipopolymer as biocompatible gene delivery agent
Salis et al. Mesoporous silica nanoparticles functionalized with hyaluronic acid and chitosan biopolymers. Effect of functionalization on cell internalization
Zhang et al. Emerging antibacterial strategies with application of targeting drug delivery system and combined treatment
US11666662B2 (en) Silica-based biomolecule carrier, pharmaceutical composition comprising the same, preparation method and use thereof
CA2444561A1 (en) Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation
WO2003028657A3 (en) Compositions for oral gene therapy and methods of using same
CA2211118A1 (en) Stable lipid-comprising drug delivery complexes and methods for their production
US20110144190A1 (en) Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
Clima et al. DyNAvectors: Dynamic constitutional vectors for adaptive DNA transfection
WO2010033733A4 (en) Folate receptor binding conjugates of antifolates
EP0848061A3 (en) Self-enhancing, pharmacologically controllable expression systems
Fei et al. Hierarchical integration of degradable mesoporous silica nanoreservoirs and supramolecular dendrimer complex as a general-purpose tumor-targeted biomimetic nanoplatform for gene/small-molecule anticancer drug co-delivery
JP2017525676A5 (en)
Perez Ruiz de Garibay Endocytosis in gene therapy with non-viral vectors
Jiang et al. Efficient gene delivery using chitosan–polyethylenimine hybrid systems
Malcolm et al. Diblock copolymer hydrophobicity facilitates efficient gene silencing and cytocompatible nanoparticle-mediated siRNA delivery to musculoskeletal cell types
Li et al. Coordination-driven self-assembly of metal ion–antisense oligonucleotide nanohybrids for chronic bacterial infection therapy
ATE338540T1 (en) POLYETHYLENE IMINE: DNA FORMULATIONS FOR AEROSOL ADMINISTRATION
CA2494541A1 (en) Shiga toxin b-subunit as a vector for tumor diagnosis and drug delivery to gb3 expressing tumors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23836258

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: AU2023303022

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/A/2024/015868

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 317868

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2023303022

Country of ref document: AU

Date of ref document: 20230706

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025500080

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 11202409123Y

Country of ref document: SG

WWE Wipo information: entry into national phase

Ref document number: 202590265

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20257003324

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020257003324

Country of ref document: KR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025000120

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 202517009892

Country of ref document: IN

Ref document number: 2023836258

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023836258

Country of ref document: EP

Effective date: 20250206

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23836258

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 202380062801.8

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020257003324

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 202517009892

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: MX/A/2024/015868

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 202380062801.8

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 202590265

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2023836258

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 112025000120

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20250103